Literature DB >> 1738194

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

H Schuitemaker1, M Koot, N A Kootstra, M W Dercksen, R E de Goede, R P van Steenwijk, J M Lange, J K Schattenkerk, F Miedema, M Tersmette.   

Abstract

The composition of human immunodeficiency virus type 1 (HIV-1) clonal populations at different stages of infection and in different compartments was analyzed. Biological HIV-1 clones were obtained by primary isolation from patient peripheral blood mononuclear cells under limiting dilution conditions, with either blood donor peripheral blood lymphocytes or monocyte-derived macrophages (MDM) as target cells, and the biological phenotype of the clones was analyzed. In asymptomatic individuals, low frequencies of HIV-1 clones were observed. These clones were non-syncytium inducing and preferentially monocytotropic. In individuals progressing to disease, a 100-fold increase in frequencies of productively HIV-1-infected cells was observed as a result of a selective expansion of nonmonocytotropic clones. In a person progressing to AIDS within 19 months after infection, only syncytium-inducing clones were detected, shifting from MDM-tropic to non-MDM-tropic over time. From his virus donor, a patient with wasting syndrome, only syncytium-inducing clones, mostly non-MDM-tropic, were recovered. Parallel clonal analysis of HIV-1 populations in cells present in bronchoalveolar lavage fluid and peripheral blood from an AIDS patient revealed a qualitatively and quantitatively more monocytotropic virus population in the lung compartment than in peripheral blood at the same time point. These findings indicate that monocytotropic HIV-1 clones, probably generated in the tissues, are responsible for the persistence of HIV-1 infection and that progression of HIV-1 infection is associated with a selective increase of T-cell-tropic, nonmonocytotropic HIV-1 variants in peripheral blood.

Entities:  

Mesh:

Year:  1992        PMID: 1738194      PMCID: PMC240857     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus.

Authors:  C Cheng-Mayer; C Weiss; D Seto; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  Differential ability of human immunodeficiency virus isolates to productively infect human cells.

Authors:  L A Evans; T M McHugh; D P Stites; J A Levy
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

3.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

4.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men.

Authors:  B F Polk; R Fox; R Brookmeyer; S Kanchanaraksa; R Kaslow; B Visscher; C Rinaldo; J Phair
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

5.  Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

Authors:  B Asjö; L Morfeldt-Månson; J Albert; G Biberfeld; A Karlsson; K Lidman; E M Fenyö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

6.  Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag.

Authors:  M Tersmette; I N Winkel; M Groenink; R A Gruters; R P Spence; E Saman; G Van Der Groen; F Miedema; J G Huisman
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

7.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

8.  Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.

Authors:  F Miedema; A J Petit; F G Terpstra; J K Schattenkerk; F de Wolf; B J Al; M Roos; J M Lange; S A Danner; J Goudsmit
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

9.  Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells.

Authors:  J D Katz; P Nishanian; R Mitsuyasu; B Bonavida
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

10.  Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro.

Authors:  R S Kornbluth; P S Oh; J R Munis; P H Cleveland; D D Richman
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  391 in total

1.  R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus.

Authors:  R D Berkowitz; A B van't Wout; N A Kootstra; M E Moreno; V D Linquist-Stepps; C Bare; C A Stoddart; H Schuitemaker; J M McCune
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step.

Authors:  Georgia D. Tomaras; Michael L. Greenberg
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

4.  The Development of Microbicides for Clinical Use to Prevent Sexually Transmitted Diseases.

Authors:  David M. Phillips; Robin A. Maguire
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

5.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 induces apoptosis in CD4(+) but not in CD8(+) T cells in ex vivo-infected human lymphoid tissue.

Authors:  J C Grivel; N Malkevitch; L Margolis
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Persistence and emergence of X4 virus in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson
Journal:  Math Biosci Eng       Date:  2011-04       Impact factor: 2.080

9.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.